News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Wyndham Worldwide Reiterates Second Quarter and Full Year Guidance
June 22, 2009
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
PRNewswire -- Wyndham Worldwide (NYSE: WYN) today reiterated adjusted EPS guidance for the second quarter of 2009 of $0.36 - $0.41 and adjusted EBITDA guidance for the full year of 2009 of $760 - $810 million.
Twitter
LinkedIn
Facebook
Email
Print